A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company · NCT07165028
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 4500
- US sites recruiting
- 137
- Study start
- October 15, 2025
- Record last updated
- October 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression.
Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.
Being studied: Tirzepatide; Retatrutide; Placebo
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Have liver fat content ≥8%
- Have ELF score of ≥9 and ≤10.8 at screening
- Have VCTE LSM ≥10 kilopascal (kPa) and \<20 kPa at screening
Exclusion Criteria
- Have any other type of liver disease other than MASLD
- Have a body mass index (BMI) \<25 kilogram per square meter (kg/m2)
- Prior decompensated liver disease (history of esophageal/gastric varices, ascites, hepatic encephalopathy)
- Have lost more than 11 pounds within the 3 months prior to screening
- Have a hemoglobin A1c (HbA1c) greater than 10%
- Have type 1 diabetes
Recruiting US locations
MFA Clinical Research
Tuscaloosa, AL 35405
Site contact: 205-331-4963
The Institute for Liver Health II dba Arizona Clinical Trials - Chandler
Chandler, AZ 85224
Site contact: Yessica Sachdeva
Spectrum Research Institute
Gilbert, AZ 85297
Site contact: Donna DeSantis
The Institute for Liver Health II dba Arizona Liver Health - Peoria
Peoria, AZ 85381
Site contact: 480-470-4000
Epic Medical Research-Sun City
Sun City, AZ 85351
Site contact: Rachel Greatwood
The Institute for Liver Health II dba Arizona Clinical Trials - Tucson
Tucson, AZ 85712
Site contact: Anita Kohli
Del Sol Research Management, LLC
Tucson, AZ 85715
Site contact: 520-257-3881
Arkansas Gastroenterology - North Little Rock
North Little Rock, AR 72117
Site contact: Samuel Dunn
San Fernando Valley Health Institute
Canoga Park, CA 91304
Site contact: 818-222-6868
Ark Clinical Research - Fountain Valley
Fountain Valley, CA 92708
Site contact: 714-988-2021
Fresno Clinical Research Center
Fresno, CA 93720
Site contact: 559-970-3441
UCSD - Altman Clinical and Translational Research Institute (ACTRI)
La Jolla, CA 92037
Site contact: 858-246-2227
Orange County Research Center
Lake Forest, CA 92630
Site contact: 714-550-9990
Om Research LLC
Lancaster, CA 93534
Site contact: 661-388-2239
Ark Clinical Research
Long Beach, CA 90815
Site contact: 562-997-1000
Los Angeles Institute for Metabolic Research
Los Angeles, CA 90015
Site contact: 213-373-8380
United Medical Doctors - Murrieta
Murrieta, CA 92563
Site contact: 951-566-5229
Knowledge Research Center
Orange, CA 92868
Site contact: 657-247-0087
California Liver Research Center
Pasadena, CA 91105
Site contact: 626-795-5769
Artemis Institute for Clinical Research
Riverside, CA 92503
Site contact: 951-374-1190
Medical Associates Research Group
San Diego, CA 92123
Site contact: 858-277-5678
Quest Clinical Research
San Francisco, CA 94115
Site contact: 415-353-0800
University of Colorado Anschutz Medical Campus
Aurora, CO 80045
Site contact: 303-724-4651
South Denver Gastroenterology
Englewood, CO 80113
Site contact: Marcelo Kugelmas
Medical Research Center of Connecticut
Hamden, CT 06518
Site contact: Paul Feuerstadt
K2 Medical Research WINTER GARDEN
Clermont, FL 34711
Site contact: 407-426-9299
K2 Medical Research - Daytona Beach
Daytona Beach, FL 32114
Site contact: Joshua Eisenhut
Care Access - Delray Beach
Delray Beach, FL 33484
Site contact: 401-773-7855
AMR Clinical
Doral, FL 33172
Site contact: Abid Chaudhry
Southwest General Healthcare Center
Fort Myers, FL 33907
Site contact: 239-931-3368
University of Florida College of Medicine
Gainesville, FL 32610
Site contact: 352-273-8662
Encore Medical Research
Hollywood, FL 33024
Site contact: 954-400-1725
Nature Coast Clinical Research - Inverness
Inverness, FL 34452
Site contact: 352-341-2100
Encore Borland-Groover Clinical Research
Jacksonville, FL 32256
Site contact: 904-680-0871
Health Awareness
Jupiter, FL 33458
Site contact: Mitchell Davis
K2 MEDICAL Research THE VILLAGES
Lady Lake, FL 32159
Site contact: 352-500-5252
Florida Research Institute
Lakewood Rch, FL 34211
Site contact: 941-727-7772
Tampa Bay Medical Research - Largo
Largo, FL 33777
Site contact: 727-724-3316
Evolution Clinical Trials
Miami, FL 33122-1722
Site contact: 786-706-1216
Floridian Clinical Research, LLC
Miami Lakes, FL 33016-1518
Site contact: 305-330-9977
GI PROS Research
Naples, FL 34102
Site contact: 239-571-0899
Charter Research - Orlando
Orlando, FL 32803
Site contact: Mary Quarterman
Headlands Research Orlando
Orlando, FL 32806
Site contact: 407-705-3471
Progressive Medical Research
Port Orange, FL 32127
Site contact: 386-304-7070
Covenant Metabolic Specialists - Riverview
Riverview, FL 33578
Site contact: 941-894-2014
Care Access - St. Petersburg
St. Petersburg, FL 33710
Site contact: 877-791-0656
Care Access - Tamarac
Tamarac, FL 33321
Site contact: 877-791-0656
Covenant Metabolic Specialists, LLC
University Park, FL 34201
Site contact: 941-894-2014
Southeast Clinical Research Center
Dalton, GA 30720
Site contact: 706-913-1779
Gastrointestinal Specialists of Georgia
Marietta, GA 30060
Site contact: 404-786-3100
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, GA 30291
Site contact: 470-317-3604
Indiana University Health University Hospital
Indianapolis, IN 46202
Site contact: 317-278-1652
Gastroenterology Health Partners
New Albany, IN 47150
Site contact: 812-206-1702
Deaconess Clinic- Gateway
Newburgh, IN 47630
Site contact: 812-490-4505
Digestive Research Alliance of Michiana
South Bend, IN 46635
Site contact: 574-904-9617
Iowa Diabetes and Endocrinology Research Center
West Des Moines, IA 50266
Site contact: Amy Keller
AMR Clinical
El Dorado, KS 67042
Site contact: 316-600-5127 EXT 301
Johnson County Clinical Trials
Lenexa, KS 66219
Site contact: Thomas Kreamer
Cotton O'Neil Digestive Health Center
Topeka, KS 66606
Site contact: 785-368-0477
AMR Clinical
Lexington, KY 40509
Site contact: Peter Akpunonu
+ 77 more on the official record.
Study contacts (from the official record)
- Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
- Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Similar studies in Alabama
All nutrition & metabolism studies in Alabama →- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Birmingham, AL + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Birmingham, AL + 112 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Birmingham, AL + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Pfizer
- Location
- Birmingham, AL + 4 other US sites
- Eligibility basics
- Ages 18+